A Promising Wet AMD Drug Misses Its Goal: What It Means for Patients

Ophthalmology Times reported that Duravyu, an investigational long-acting treatment, missed its main goal in a wet macular degeneration trial again, and its maker, EyePoint, is now shifting focus toward diabetic macular edema (DME).

Background

Wet age-related macular degeneration (AMD) causes abnormal blood vessels to grow under the retina and leak, damaging central vision. Standard treatment is regular injections of anti-VEGF medicine, often every one to three months. Long-acting treatments such as Duravyu aim to stretch that interval so patients need fewer visits and injections.

Why a “missed end point” matters

Every clinical trial sets a primary end point, a main measure of success decided in advance. Missing it means the trial did not prove the benefit researchers were looking for. It does not always mean a drug has no value, which is why the company is exploring a different disease. But it does mean the treatment is not ready for wet AMD patients.

The takeaway for patients

• Current anti-VEGF treatments remain highly effective; keep your scheduled injections.
• Many other long-acting approaches are in development, including gene therapies and implants.
• Ask your retina specialist about clinical trials if frequent visits are a burden.

Know the signs of wet AMD

Sudden distortion, wavy lines, or a new dark spot in central vision should be checked within days, not weeks. Early treatment protects more vision.

Eye care for Oak Park and Westlake Village

Khanna Vision Institute, located in Westlake Village, provides comprehensive eye exams for Oak Park families. We do not treat macular degeneration; when we detect it, we refer patients to trusted retina specialists and help coordinate care, including cataract surgery when it is needed.

More eye-health articles at Pi In Eye.

Source: Duravyu misses wet AMD end point again as EyePoint pivots to DME | Eye Care Network – Modern Retina (Ophthalmology Times, 10/20/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.